Compass Therapeutics Q3 net loss widens on higher R&D expenses

Compass Therapeutics Q3 net loss widens on higher R&D expenses


Overview

  • Oncology biopharma reported Q3 net loss widened yr/yr on higher R&D and G&A expenses

  • Company ended Q3 with $163 mln in cash and marketable securities, runway projected into 2028

  • Company advancing BLA submission for tovecimig in biliary tract cancer despite FDA request for more data


Outlook

  • Company plans to advance BLA submission for tovecimig in BTC despite FDA request for new trial

  • Company expects update on CTX-8371 Phase 1 cohort expansions later this year

  • Update on CTX-10726 Phase 1 dose-escalation study anticipated later this year


Result Drivers

  • TOVECIMIG MANUFACTURING COSTS - Higher R&D expenses in Q3 mainly due to increased manufacturing costs for tovecimig

  • PRE-COMMERCIALIZATION SPENDING - G&A expenses rose due to increased stock-based compensation and pre-commercialization costs


Company press release: ID:nGNX8njxd4


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$27.17 mln

Q3 Income From Operations

-$28.8 mln

Q3 Loss Per Basic Share

$0.15


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Compass Therapeutics Inc. is $6.00, about 690.7% above its November 6 closing price of $0.76


Reuters Recommended Reads

  • Nov 9 - Bicara Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 9 - Neurogene Q3 net loss widens on higher R&D and G&A costs

  • Nov 9 - Praxis Precision Q3 net loss widens to $94 mln on G&A costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Compass Therapeutics

See all news